4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) is anticipated to post its Q4 2024 quarterly earnings results before the market opens on Friday, February 28th. Analysts expect 4D Molecular Therapeutics to post earnings of ($0.80) per share and revenue of $2.28 million for the quarter.
4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its earnings results on Friday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.10). On average, analysts expect 4D Molecular Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
4D Molecular Therapeutics Stock Up 1.1 %
FDMT traded up $0.05 during midday trading on Friday, reaching $4.53. The company had a trading volume of 1,233,187 shares, compared to its average volume of 846,836. The business has a 50-day moving average of $5.22 and a two-hundred day moving average of $8.59. 4D Molecular Therapeutics has a 1 year low of $4.20 and a 1 year high of $36.25. The company has a market cap of $209.41 million, a P/E ratio of -1.59 and a beta of 2.81.
Analyst Ratings Changes
A number of research firms have commented on FDMT. Weiss Ratings restated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, February 19th. Chardan Capital decreased their price objective on shares of 4D Molecular Therapeutics from $39.00 to $30.00 and set a "buy" rating on the stock in a research report on Tuesday, February 11th. HC Wainwright restated a "buy" rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Monday, February 10th. Bank of America cut their price target on 4D Molecular Therapeutics from $79.00 to $46.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. Finally, Morgan Stanley lowered their price objective on 4D Molecular Therapeutics from $8.00 to $6.00 and set an "underweight" rating on the stock in a research report on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $32.13.
View Our Latest Analysis on 4D Molecular Therapeutics
4D Molecular Therapeutics Company Profile
(
Get Free Report)
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
See Also
Before you consider 4D Molecular Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.
While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
